{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T03:27:02Z","timestamp":1777865222982,"version":"3.51.4"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81673299"],"award-info":[{"award-number":["81673299"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81273376"],"award-info":[{"award-number":["81273376"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.ejmech.2019.06.087","type":"journal-article","created":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T01:37:13Z","timestamp":1561945033000},"page":"608-622","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Design, synthesis and biological evaluation of novel FFA1\/GPR40 agonists: New breakthrough in an old scaffold"],"prefix":"10.1016","volume":"179","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8067-9700","authenticated-orcid":false,"given":"Zheng","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunxia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianyong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaqi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiwen","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dazhi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayi","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenlong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3827-0992","authenticated-orcid":false,"given":"Hai","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2019.06.087_bib1","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2337\/db09-9028","article-title":"From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus","volume":"58","author":"DeFronzo","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.ejmech.2019.06.087_bib2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(11)60679-X","article-title":"Burden Metab Risk Factors, National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants","volume":"378","author":"Danaei","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2019.06.087_bib3","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1210\/10.1210\/er.2006-0038","article-title":", beta-cell failure in diabetes and preservation by clinical treatment","volume":"28","author":"Wajchenberg","year":"2007","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.ejmech.2019.06.087_bib4","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1210\/jc.2004-0699","article-title":"Sulfonylurea induced beta-cell apoptosis in cultured human islets","volume":"90","author":"Maedler","year":"2005","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejmech.2019.06.087_bib5","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1080\/13543784.2016.1189530","article-title":"Free fatty acid receptor agonists for the treatment of type 2 diabetes: drugs in preclinical to phase II clinical development","volume":"25","author":"Li","year":"2016","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.ejmech.2019.06.087_bib6","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nature01478","article-title":"Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40","volume":"422","author":"Itoh","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2019.06.087_bib7","doi-asserted-by":"crossref","first-page":"11303","DOI":"10.1074\/jbc.M211495200","article-title":"The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids","volume":"278","author":"Briscoe","year":"2003","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2019.06.087_bib8","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.2337\/db08-0307","article-title":"Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion","volume":"57","author":"Edfalk","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.ejmech.2019.06.087_bib9","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1517\/14728222.11.5.661","article-title":"Fatty acid receptors as new therapeutic targets for diabetes","volume":"11","author":"Rayasam","year":"2007","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ejmech.2019.06.087_bib10","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/med.21441","article-title":"Free fatty acid receptor 1 (FFAR1) as an emerging therapeutic target for type 2 diabetes mellitus: recent progress and prevailing challenges","volume":"38","author":"Li","year":"2018","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2019.06.087_bib11","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1021\/jm101405t","article-title":"Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists","volume":"54","author":"Sasaki","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.087_bib12","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1021\/ml1000855","article-title":"Discovery of TAK-875: a potent, selective, and orally bioavailable GPR40 agonist","volume":"1","author":"Negoro","year":"2010","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2019.06.087_bib13","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1021\/jm2016123","article-title":"Discovery of phenylpropanoic acid derivatives containing polar functionalities as potent and orally bioavailable G protein-coupled receptor 40 agonists for the treatment of type 2 diabetes","volume":"55","author":"Mikami","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.087_bib14","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1021\/jm300170m","article-title":"Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40\/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent","volume":"55","author":"Negoro","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.087_bib15","doi-asserted-by":"crossref","first-page":"10891","DOI":"10.1021\/acs.jmedchem.6b00892","article-title":"The discovery, preclinical, and early clinical development of potent and selective GPR40 agonists for the treatment of type 2 diabetes mellitus (LY2881835, LY2922083, and LY2922470)","volume":"59","author":"Hamdouchi","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.087_bib16","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.bmcl.2011.10.118","article-title":"AMG 837: a potent, orally bioavailable GPR40 agonist","volume":"22","author":"Houze","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.06.087_bib17","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/j.bmcl.2006.12.084","article-title":"Solid phase synthesis and SAR of small molecule agonists for the GPR40 receptor","volume":"17","author":"McKeown","year":"2007","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.06.087_bib18","doi-asserted-by":"crossref","first-page":"7061","DOI":"10.1021\/jm8010178","article-title":"Discovery of potent and selective agonists for the free fatty acid receptor 1 (FFA(1)\/GPR40), a potential target for the treatment of type II diabetes","volume":"51","author":"Christiansen","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.087_bib19","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1021\/acs.jmedchem.6b01559","article-title":"Discovery of pyrrolidine-containing GPR40 agonists: stereochemistry effects a change in binding mode","volume":"60","author":"Jurica","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.087_bib20","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1021\/acs.jmedchem.7b00982","article-title":"Discovery of potent and orally bioavailable dihydropyrazole GPR40 agonists","volume":"61","author":"Shi","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.087_bib21","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1021\/acs.jmedchem.6b01357","article-title":"Discovery of potent and orally bioavailable GPR40 full agonists bearing thiophen-2-ylpropanoic acid scaffold","volume":"60","author":"Li","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.087_bib22","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.4155\/fmc-2017-0113","article-title":"Quercetin\/oleic acid-based G-protein-coupled receptor 40 ligands as new insulin secretion modulators","volume":"9","author":"Badolato","year":"2017","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.087_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2019.05.018","article-title":"Quercetin-3-oleoyl derivatives as new GPR40 agonists: molecular docking studies and functional evaluation","author":"Carullo","year":"2019","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.06.087_bib24","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1517\/13543784.2014.964859","article-title":"Discontinued in 2013: diabetic drugs","volume":"23","author":"Hedrington","year":"2014","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.ejmech.2019.06.087_bib25","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/dom.12467","article-title":"Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial","volume":"17","author":"Kaku","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.ejmech.2019.06.087_bib26","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/dom.12693","article-title":"Long-term safety and efficacy of fasiglifam (TAK-875), a G-protein-coupled receptor 40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52-week open-label phase III study","volume":"18","author":"Kaku","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.ejmech.2019.06.087_bib27","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3389\/fendo.2014.00152","article-title":"The G-protein-coupled long-chain fatty acid receptor GPR40 and glucose metabolism","volume":"5","author":"Tomita","year":"2014","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ejmech.2019.06.087_bib28","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1021\/acs.chemrev.6b00056","article-title":"Complex pharmacology of free fatty acid receptors","volume":"117","author":"Milligan","year":"2017","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2019.06.087_bib29","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1124\/dmd.115.064121","article-title":"Fasiglifam (TAK-875) inhibits hepatobiliary transporters: a possible factor contributing to fasiglifam-induced liver injury","volume":"43","author":"Li","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejmech.2019.06.087_bib30","first-page":"50","article-title":"Fasiglifam (TAK-875) alters bile acid homeostasis in rats and dogs: a potential cause of drug induced liver injury","volume":"157","author":"Wolenski","year":"2017","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.ejmech.2019.06.087_bib31","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/toxsci\/kfx040","article-title":"Fasiglifam (TAK-875): mechanistic investigation and retrospective identification of hazards for drug induced liver injury","volume":"163","author":"Otieno","year":"2018","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.ejmech.2019.06.087_bib32","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ejmech.2016.02.040","article-title":"Design, synthesis and Structure-activity relationship studies of new thiazole-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes","volume":"113","author":"Li","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.087_bib33","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/j.bmc.2016.03.014","article-title":"Discovery of novel pyrrole-based scaffold as potent and orally bioavailable free fatty acid receptor 1 agonists for the treatment of type 2 diabetes","volume":"24","author":"Li","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.087_bib34","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1016\/j.bmc.2016.08.068","article-title":"Discovery of novel free fatty acid receptor 1 agonists bearing triazole core via click chemistry","volume":"24","author":"Li","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.087_bib35","doi-asserted-by":"crossref","first-page":"46356","DOI":"10.1039\/C6RA07356E","article-title":"Discovery of a novel oxime ether scaffold as potent and orally bioavailable free fatty acid receptor 1 agonists","volume":"6","author":"Li","year":"2016","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2019.06.087_bib36","doi-asserted-by":"crossref","first-page":"6666","DOI":"10.1016\/j.bmc.2015.09.010","article-title":"Design, synthesis and structure-activity relationship studies of novel phenoxyacetamide-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes","volume":"23","author":"Li","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.087_bib37","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1016\/j.bmc.2017.03.001","article-title":"Design, synthesis and structure-activity relationship studies of novel free fatty acid receptor 1 agonists bearing amide linker","volume":"25","author":"Yang","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.087_bib38","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ejmech.2017.07.001","article-title":"Discovery of phenylsulfonyl acetic acid derivatives with improved efficacy and safety as potent free fatty acid receptor 1 agonists for the treatment of type 2 diabetes","volume":"138","author":"Li","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.087_bib39","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/j.bmcl.2006.01.007","article-title":"Synthesis and activity of small molecule GPR40 agonists","volume":"16","author":"Garrido","year":"2006","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.06.087_bib40","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.bmc.2014.11.016","article-title":"Synthesis and biological evaluation of phenoxyacetic acid derivatives as novel free fatty acid receptor 1 agonists","volume":"23","author":"Wang","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.087_bib41","doi-asserted-by":"crossref","first-page":"7158","DOI":"10.1016\/j.bmc.2015.10.011","article-title":"Design, synthesis and biological activity of phenoxyacetic acid derivatives as novel free fatty acid receptor 1 agonists","volume":"23","author":"Li","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.087_bib42","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.addr.2012.09.019","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"64","author":"Lipinski","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejmech.2019.06.087_bib43","doi-asserted-by":"crossref","first-page":"6691","DOI":"10.1021\/jm2005699","article-title":"Identification of a potent and selective free fatty acid receptor 1 (FFA1\/GPR40) agonist with favorable physicochemical and in\u00a0vitro ADME properties","volume":"54","author":"Christiansen","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.087_bib44","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1517\/17460441003605098","article-title":"Lipophilicity in drug discovery","volume":"5","author":"Waring","year":"2010","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2019.06.087_bib45","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd2796","article-title":"The influence of lead discovery strategies on the properties of drug candidates","volume":"8","author":"Keser\u00fc","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2019.06.087_bib46","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1021\/acsmedchemlett.5b00157","article-title":"Molecular property design: does everyone get it?","volume":"6","author":"Leeson","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2019.06.087_bib47","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S1359-6446(04)03069-7","article-title":"Ligand efficiency: a useful metric for lead selection","volume":"9","author":"Hopkins","year":"2004","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2019.06.087_bib48","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/nrd2445","article-title":"The influence of drug-like concepts on decision-making in medicinal chemistry","volume":"6","author":"Leeson","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2019.06.087_bib49","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1021\/j100785a001","article-title":"van der Waals volumes and radii","volume":"68","author":"Bondi","year":"1964","journal-title":"J.\u00a0Phys. Chem."},{"key":"10.1016\/j.ejmech.2019.06.087_bib50","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejmech.2016.03.054","article-title":"Synthesis and biological evaluation of GPR40\/FFAR1 agonists containing 3,5-dimethylisoxazole","volume":"116","author":"Yang","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.087_bib51","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/nature13494","article-title":"High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875","volume":"513","author":"Srivastava","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2019.06.087_bib52","doi-asserted-by":"crossref","first-page":"6450","DOI":"10.1021\/jm701280z","article-title":"8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes","volume":"50","author":"Eckhardt","year":"2007","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.06.087_bib53","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S0026-0495(98)90027-0","article-title":"Nongenetic mouse models of non-insulin-dependent diabetes mellitus","volume":"47","author":"Luo","year":"1998","journal-title":"Metabolism"},{"key":"10.1016\/j.ejmech.2019.06.087_bib54","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3109\/03602530903491881","article-title":"Sandwich-cultured hepatocytes: an in\u00a0vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity","volume":"42","author":"Swift","year":"2010","journal-title":"Drug Metab. Rev."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419306142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419306142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T05:57:39Z","timestamp":1777528659000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523419306142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":54,"alternative-id":["S0223523419306142"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.06.087","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and biological evaluation of novel FFA1\/GPR40 agonists: New breakthrough in an old scaffold","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.06.087","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}